The FDA, journals, and even payors are encouraging labs to deposit variant data in public databases, but collaboration is needed to resolve interpretation discrepancies.
Ranomics is building a business around providing functional data on variants of unknown significance, starting with BRCA1 mutations.
Inova is using Translational's platform to evaluate data from MediMap, a new test that evaluates pharmacogenetics markers in seven genes in newborns.
The international group has released a second tier of public data so researchers and genetic counselors can see information on specific variants across databases.
Fujitsu has developed a method of aggregating genomic information that makes it easier and quicker to query large numbers of variants for GWAS.
The Simons Simplex Collection of genomic data from 2,600 simplex autism families is accessible through WuXi NextCode's cloud-based database.
As the genomics field increasingly recognizes the importance of data sharing, Ambry has upped the ante by sequencing thousands of exomes and launching an open database.
Ambry Genetics is to make aggregated customer data publicly available, the New York Times says.
Questions about the ethics of alerting people to their cancer risk without their consent have frustrated DeCode Genetics' vision of using genetics to improve public health.
The collaboration will focus on identifying new signaling pathways and targets involved in coronary artery disease.
At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.
The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.
Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.
In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.